Send us Feedback

Celgene (CELG)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

CELG » Topics » We have entered into a definitive agreement to acquire Pharmion, subject to certain closing conditions, including the appropriate affirmative vote of Pharmion stockholders. The integration of Pharmion and other acquired businesses may present significant

These excerpts taken from the CELG 10-K filed Feb 20, 2008.
We have entered into a definitive agreement to acquire Pharmion, subject to certain closing conditions, including the appropriate affirmative vote of Pharmion stockholders. The integration of Pharmion and other acquired businesses may present significant challenges to us.
 
Achieving the anticipated benefits of our pending acquisition of Pharmion will depend in part upon whether we and Pharmion can integrate our businesses in an efficient and effective manner. In addition, we may acquire additional businesses from time to time. The integration of Pharmion and any future businesses that we may acquire involves a number of risks, including, but not limited to:
 
  •  demands on management related to the increase in our size after the acquisition;
 
  •  the diversion of management’s attention from the management of daily operations to the integration of operations;
 
  •  higher integration costs than anticipated;
 
  •  failure to achieve expected synergies and costs savings;
 
  •  difficulties in the assimilation and retention of employees;
 
  •  difficulties in the assimilation of different cultures and practices, as well as in the assimilation of broad and geographically dispersed personnel and operations; and
 
  •  difficulties in the integration of departments, systems, including accounting systems, technologies, books and records, and procedures, as well as in maintaining uniform standards, controls, including internal control over financial reporting required by the Sarbanes-Oxley Act of 2002 and related procedures and policies.
 
If we cannot successfully integrate Pharmion or other acquired businesses, we may experience material negative consequences to our business, financial condition or results of operations. Successful integration of Pharmion and other acquired businesses will depend on our ability to manage these operations, to realize opportunities for revenue growth presented by offerings and expanded geographic market coverage and, to some degree, to eliminate redundant and excess costs. Because of difficulties in combining geographically distant operations, we may not be able to achieve the benefits that we hope to achieve as a result of the merger with Pharmion or other acquired businesses.
 
We
have entered into a definitive agreement to acquire Pharmion,
subject to certain closing conditions, including the appropriate
affirmative vote of Pharmion stockholders. The integration of
Pharmion and other acquired businesses may present significant
challenges to us.


 



Achieving the anticipated benefits of our pending acquisition of
Pharmion will depend in part upon whether we and Pharmion can
integrate our businesses in an efficient and effective manner.
In addition, we may acquire additional businesses from time to
time. The integration of Pharmion and any future businesses that
we may acquire involves a number of risks, including, but not
limited to:


 












































































  • 
demands on management related to the increase in our size after
the acquisition;
 
  • 
the diversion of management’s attention from the management
of daily operations to the integration of operations;
 
  • 
higher integration costs than anticipated;
 
  • 
failure to achieve expected synergies and costs savings;
 
  • 
difficulties in the assimilation and retention of employees;
 
  • 
difficulties in the assimilation of different cultures and
practices, as well as in the assimilation of broad and
geographically dispersed personnel and operations; and
 
  • 
difficulties in the integration of departments, systems,
including accounting systems, technologies, books and records,
and procedures, as well as in maintaining uniform standards,
controls, including internal control over financial reporting
required by the Sarbanes-Oxley Act of 2002 and related
procedures and policies.


 



If we cannot successfully integrate Pharmion or other acquired
businesses, we may experience material negative consequences to
our business, financial condition or results of operations.
Successful integration of Pharmion and other acquired businesses
will depend on our ability to manage these operations, to
realize opportunities for revenue growth presented by offerings
and expanded geographic market coverage and, to some degree, to
eliminate redundant and excess costs. Because of difficulties in
combining geographically distant operations, we may not be able
to achieve the benefits that we hope to achieve as a result of
the merger with Pharmion or other acquired businesses.


 




EXCERPTS ON THIS PAGE:

10-K (2 sections)
Feb 20, 2008

RELATED TOPICS for CELG:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki